Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis

Yusuke Sakamaki, Hiroyuki Sasamura, Kaori Hayashi, Kimiko Ishiguro, Hironari Takaishi, Yasunori Okada, Jeanine M. D'Armiento, Takao Saruta, Hiroshi Itoh

研究成果: Article査読

18 被引用数 (Scopus)


Background/Aims: The role of matrix metalloproteinases (MMPs) in the pathogenesis of glomerular injury appears to be complex. To investigate the role of individual MMPs, we examined the course of Adriamycin-induced albuminuria and glomerulosclerosis in mice lacking either a gelatinase (MMP-9) or a collagenase (MMP-13). Methods: Adriamycin was administered to MMP-9 or MMP-13 knockout (KO) mice. Glomerular injury was assessed by the quantification of albuminuria, the glomerular injury score and type IV collagen immunostaining. Results: Treatment of mice with Adriamycin (18 mg/kg i.v.) resulted in marked albuminuria and glomerulosclerosis reaching a peak at 4-8 weeks. The albuminuria and glomerulosclerosis were significantly (p < 0.05) attenuated in both the MMP-9 KO and MMP-13 KO mice compared to controls. In contrast, treatment of wild-type mice with the broad-spectrum MMP inhibitor doxycycline did not have a beneficial effect on the albuminuria and glomerulosclerosis. Conclusion: These results support a role for both gelatinase (MMP-9) and collagenase (MMP-13) in the pathogenesis of glomerular injury in the Adriamycin-induced glomerulosclerosis model. MMP inhibitors with high specificity towards MMP-9 and/or MMP-13 may be potential future candidates to provide more effective therapies to inhibit the development of glomerulosclerosis.

ジャーナルNephron - Experimental Nephrology
出版ステータスPublished - 2010 6月

ASJC Scopus subject areas

  • 生理学
  • 遺伝学
  • 腎臓病学


「Absence of gelatinase (MMP-9) or collagenase (MMP-13) attenuates adriamycin-Induced albuminuria and glomerulosclerosis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。